Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Patient Comfort × Other hematologic neoplasm × Clear all
NCT03870750 2026-01-12

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Fred Hutchinson Cancer Center

Phase 2/3 Terminated
458 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡